Answers are grounded in this paper and cite their sources.
Photoactivated Ru(II) polypyridyl complexes containing diprotic ligands and extended π systems have been synthesized and investigated as anticancer agents in cell studies. The DNA binding properties of the photoactivated ruthenium complexes [(bphen) 2 Ru(4,4′‐dhbp)]Cl 2 ( 1 A ), [(dppz) 2 Ru(4,4′‐dhbp)]Cl 2 ( 2 A ), [(bphen) 2 Ru(4,7‐dhphen)]Cl 2 ( 3 A ), and [(dppz) 2 Ru(4,7‐dhphen)]Cl 2 ( 4 A ) were investigated to further characterize these compounds and their mode of action (where bphen = bathophenanthroline, dppz = dipyrido[3,2‐a:2′,3′‐c]phenazine, 4,4′‐dhbp = 4,4′‐dihydroxy‐2,2′‐bipyridine, and 4,7‐dhphen = 4,7‐dihydroxy‐1,10‐phenanthroline). Initial studies probed the DNA binding ability of these compounds by circular dichroism and UV–Visible spectroscopy, and these methods were suggestive of DNA binding but not quantitative. DNA binding was further investigated by fluorescence emission quenching in a competitive binding assay, with each Ru complex displacing ethidium bromide. Ru compounds were evaluated relative to the weak DNA binder [Ru(bpy) 3 ]Cl 2 ( Lit‐1 ) and the known DNA intercalator [(phen) 2 Ru(dppz)]Cl 2 ( Lit‐2 ). Stern‐Volmer quenching constants and competitive binding constants were determined for each compound. Trends in binding affinity indicate the role of pH‐sensitive ligand charge in binding DNA, providing further insight into the structure–activity relationship of these compounds.
No takes yet. Share an insight, caveat, or question.
Kuehner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: